Table 1.
Tumour characteristics at first diagnosis and prior treatments—PP population
| Trabectedin N = 115 |
|
|---|---|
| Stage at first diagnosis, n (%) | |
| IA | 9 (8.0) |
| IB | 49 (43.4) |
| IIA | 10 (8.8) |
| IIB | 4 (3.5) |
| IIIA | 8 (7.1) |
| IIIB | 2 (1.8) |
| IVA | 9 (8.0) |
| IVB | 22 (19.5) |
| Missing | 2 |
| Surgery for primary disease, n (%) | 115 (100) |
| Total abdominal hysterectomy + bilateral salpingo oophorectomy | 88 (76.5) |
| Hysterectomy | 25 (21.7) |
| Other | 2 (1.7) |
| Lymphadenectomy, n (%) | 22 (22.4) |
| Missing | 17 |
| Adjuvant radiotherapy, n (%) | 14 (12.2) |
| Site of external beam radiotherapy, n (%) | |
| Pelvic | 12 (92.3) |
| Other | 1 (7.7) |
| Missing | 1 |
| Previous chemotherapies, n (%) | |
| Only adjuvant | 40 (34.8) |
| Only first-line | 32 (27.8) |
| Adjuvant plus first-line | 23 (20.0) |
| First and second-line | 15 (13.0) |
| Adjuvant plus first-line and second-line | 4 (3.5) |
| Adjuvant plus first-line (unknown second-line) | 1 (0.9) |
| Adjuvant chemotherapy, n (%) | 68 (59.1) |
| Anthracyclines | 41 (60.3) |
| Gemcitabine | 27 (39.7) |
| First-line chemotherapy, n (%) | 75 (65.2) |
| Anthracyclines | 39 (52.0) |
| Gemcitabine | 34 (45.3) |
| Other | 2 (2.7) |
| Second-line chemotherapy, n (%) | 19 (16.7) |
| Anthracyclines | 2 (10.5) |
| Gemcitabine | 12 (63.2) |
| Other | 5 (26.3) |